Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Tatsushi Shingai"'
Autor:
Taishi Hata, Mamoru Uemura, Katsuki Danno, Shinichi Yoshioka, Chu Matsuda, Yoshinori Kagawa, Tatsushi Shingai, Yozo Suzuki, Mitsuyoshi Tei, Tsukasa Tanida, Takamichi Komori, Shu Okamura, Hirofumi Ota, Hiroyoshi Takemoto, Takayuki Ogino, Norikatsu Miyoshi, Hirofumi Yamamoto, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Adjuvant oxaliplatin plus capecitabine (XELOX) therapy is recommended for patients with curatively resected colon cancer. However, prospective data on its practical application in Japanese patients are limited. Therefore, we aimed to conduct
Externí odkaz:
https://doaj.org/article/8397edc0e89c4d1c838969c4c7173351
Autor:
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Purpose Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treat
Externí odkaz:
https://doaj.org/article/8e277a2749b9411aa5325e80e6e2203a
Autor:
Junichi Nishimura, Junichi Hasegawa, Shingo Noura, Kimimasa Ikeda, Masayoshi Yasui, Takamichi Komori, Masaki Tsujie, Keigo Yasumasa, Tatsushi Shingai, Mamoru Uemura, Taishi Hata, Chu Matsuda, Tsunekazu Mizushima, Masataka Ikeda, Yuichiro Doki, Masaki Mori
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 4, Iss 3, Pp 108-113 (2020)
Objectives: We previously reported the feasibility of neoadjuvant capecitabine and oxaliplatin plus bevacizumab as a treatment for locally advanced rectal cancer (UMIN000003219). The aim of this study is to investigate the prognostic relevance of neo
Externí odkaz:
https://doaj.org/article/b2e4b6ced8f6465abef3906be13a2ad3
Autor:
Akira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 5, Pp 1779-1789 (2020)
Abstract Background It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with th
Externí odkaz:
https://doaj.org/article/17e4563d1d4c4391ab789022af8e5e46
Autor:
Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Sudo, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 7, Iss 9, Pp 4217-4227 (2018)
Abstract A prospective trial has not been performed to investigate associations between quality of life (QOL), adverse events (AEs), and overall survival (OS) in the first‐line treatment with cetuximab plus standard chemotherapy for advanced/metast
Externí odkaz:
https://doaj.org/article/752e48f504594ec88fe13ab55e417cca
Autor:
Hirotada Kittaka, Hidenori Takahashi, Hiroaki Ohigashi, Kunihito Gotoh, Terumasa Yamada, Tatsushi Shingai, Masaaki Motoori, Kentaro Kishi, Shingo Noura, Yoshiyuki Fujiwara, Masayuki Ohue, Yasuhiko Tomita, Masahiko Yano, Osamu Ishikawa
Publikováno v:
Case Reports in Gastroenterology, Vol 6, Iss 2, Pp 518-522 (2012)
Pancreatic acinar cell carcinoma (ACC) is a rare tumor, and its pathophysiology has not been well understood. Treatment strategies for hepatic metastasis originating from ACC remain controversial. We report the case of a 66-year-old woman who had und
Externí odkaz:
https://doaj.org/article/e6ebda80defd4f31bf7e797698f31334
Autor:
Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Katsuya Ohta, Hironaga Satake, Shingo Noura, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Toshimasa Tsujinaka, Taroh Satoh
Publikováno v:
The Oncologist.
Background We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b71ed2121a693c1f39e96026bb5656
https://doi.org/10.1093/oncolo/oyac145
https://doi.org/10.1093/oncolo/oyac145
Autor:
Anna Tsutsui, Hiroyoshi Takemoto, Hideki Osawa, Ho Min Kim, Tsunekazu Mizushima, Yuichiro Doki, Tatsushi Shingai, Yuko Ohno, Ken Konishi, Mitsuyoshi Tei, Hidetoshi Eguchi, Taishi Hata, Chu Matsuda, Masakazu Ikenaga, Kohei Murata, Kiyotaka Hagihara, Masayuki Ohue, Mamoru Uemura, Hiroki Akamatsu
Publikováno v:
The Oncologist
Lessons Learned The 3-year disease-free survival rate of the twice-daily regimen was not inferior to that of the conventional three-times-daily regimen, and the twice-daily regimen did not lead to an increase in adverse events. The effectiveness of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f699a9132ff11d000a4244ce97978d
https://doi.org/10.1002/onco.13724
https://doi.org/10.1002/onco.13724
Autor:
Hiroaki Tanioka, Masahito Kotaka, Yasuhiro Miyake, Taichi Yabuno, Hironaga Satake, Takeshi Suto, Tatsushi Shingai, Masato Kataoka, Hiroki Hara, Masato Nakamura, Masashi Ishikawa, Yoshinori Kagawa, Akira Ooki, Junichi Sakamoto, Shigeyoshi Iwamoto, Kensei Yamaguchi, Masahiko Ando, Satoshi Morita, Yojiro Hashiguchi, Akihito Tsuji
Publikováno v:
Cancer Medicine
The status and prognostic value of the disagreement between physician and patient assessments of symptomatic adverse events (AEs) remain unclear for patients with metastatic colorectal cancer treated with first‐line cetuximab plus chemotherapy. Pai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1d3e8a2e13fedd2df805a7b8e7df61
https://doi.org/10.1002/cam4.3564
https://doi.org/10.1002/cam4.3564
Autor:
Tatsushi Shingai, Mamoru Uemura, Takamichi Komori, Taishi Hata, Masaki Tsujie, Tsunekazu Mizushima, Kimimasa Ikeda, Junichi Nishimura, Masayoshi Yasui, Keigo Yasumasa, Masataka Ikeda, Yuichiro Doki, Masaki Mori, Shingo Noura, Chu Matsuda, Junichi Hasegawa
Publikováno v:
Journal of the Anus, Rectum and Colon
Journal of the Anus, Rectum and Colon, Vol 4, Iss 3, Pp 108-113 (2020)
Journal of the Anus, Rectum and Colon, Vol 4, Iss 3, Pp 108-113 (2020)
Objectives We previously reported the feasibility of neoadjuvant capecitabine and oxaliplatin plus bevacizumab as a treatment for locally advanced rectal cancer (UMIN000003219). The aim of this study is to investigate the prognostic relevance of neoa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c4e5f19cb1c926213a84c8284b877f3
https://doi.org/10.23922/jarc.2019-042
https://doi.org/10.23922/jarc.2019-042